Literature DB >> 35702495

Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

Kerstin Rhiem1, Bernd Auber2, Susanne Briest3, Nicola Dikow4, Nina Ditsch5, Neda Dragicevic6, Sabine Grill7, Eric Hahnen1, Judit Horvath8, Bernadette Jaeger9, Karin Kast1, Marion Kiechle7, Elena Leinert10, Susanne Morlot2, Michael Püsken11, Dieter Schäfer12, Sarah Schott13, Christopher Schroeder14, Ulrike Siebers-Renelt8, Christine Solbach15, Nana Weber-Lassalle1, Isabell Witzel16, Christine Zeder-Göß5, Rita K Schmutzler1.   

Abstract

Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk®) for the analysis of risk genes for familial breast and ovarian cancer. Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process. Key Messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  BRCA1; BRCA2; Consensus; Hereditary breast cancer; Hereditary ovarian cancer; Panel testing

Year:  2021        PMID： 35702495      PMCID： PMC9149395          DOI： 10.1159/000516376

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.268


  52 in total

1.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

2.  Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria.

Authors:  Rosa M Xicola; Shuwei Li; Nicolette Rodriguez; Patrick Reinecke; Rachid Karam; Virginia Speare; Mary Helen Black; Holly LaDuca; Xavier Llor
Journal:  J Med Genet       Date:  2019-07-11       Impact factor: 6.318

3.  Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

Authors:  Ella R Thompson; Simone M Rowley; Na Li; Simone McInerny; Lisa Devereux; Michelle W Wong-Brown; Alison H Trainer; Gillian Mitchell; Rodney J Scott; Paul A James; Ian G Campbell
Journal:  J Clin Oncol       Date:  2016-01-19       Impact factor: 44.544

4.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Authors:  Kelly A Metcalfe; Aletta Poll; Robert Royer; Marcia Llacuachaqui; Anna Tulman; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.

Authors:  Anh N Le; Joanna Harton; Heena Desai; Jacquelyn Powers; Kristin Zelley; Angela R Bradbury; Katherine L Nathanson; Payal D Shah; Abigail Doucette; Gary M Freedman; Peter Gabriel; Susan M Domchek; Suzanne P MacFarland; Kara N Maxwell
Journal:  Breast Cancer Res Treat       Date:  2020-04-03       Impact factor: 4.872

6.  High frequency of de novo mutations in Li-Fraumeni syndrome.

Authors:  K D Gonzalez; C H Buzin; K A Noltner; D Gu; W Li; D Malkin; S S Sommer
Journal:  J Med Genet       Date:  2009-06-25       Impact factor: 6.318

Review 7.  Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

Authors:  Rachel S van der Post; Ingrid P Vogelaar; Fátima Carneiro; Parry Guilford; David Huntsman; Nicoline Hoogerbrugge; Carlos Caldas; Karen E Chelcun Schreiber; Richard H Hardwick; Margreet G E M Ausems; Linda Bardram; Patrick R Benusiglio; Tanya M Bisseling; Vanessa Blair; Eveline Bleiker; Alex Boussioutas; Annemieke Cats; Daniel Coit; Lynn DeGregorio; Joana Figueiredo; James M Ford; Esther Heijkoop; Rosella Hermens; Bostjan Humar; Pardeep Kaurah; Gisella Keller; Jennifer Lai; Marjolijn J L Ligtenberg; Maria O'Donovan; Carla Oliveira; Hugo Pinheiro; Krish Ragunath; Esther Rasenberg; Susan Richardson; Franco Roviello; Hans Schackert; Raquel Seruca; Amy Taylor; Anouk Ter Huurne; Marc Tischkowitz; Sheena Tjon A Joe; Benjamin van Dijck; Nicole C T van Grieken; Richard van Hillegersberg; Johanna W van Sandick; Rianne Vehof; J Han van Krieken; Rebecca C Fitzgerald
Journal:  J Med Genet       Date:  2015-05-15       Impact factor: 6.318

8.  BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.

Authors:  Nana Weber-Lassalle; Jan Hauke; Juliane Ramser; Lisa Richters; Eva Groß; Britta Blümcke; Andrea Gehrig; Anne-Karin Kahlert; Clemens R Müller; Karl Hackmann; Ellen Honisch; Konstantin Weber-Lassalle; Dieter Niederacher; Julika Borde; Holger Thiele; Corinna Ernst; Janine Altmüller; Guido Neidhardt; Peter Nürnberg; Kristina Klaschik; Christopher Schroeder; Konrad Platzer; Alexander E Volk; Shan Wang-Gohrke; Walter Just; Bernd Auber; Christian Kubisch; Gunnar Schmidt; Judit Horvath; Barbara Wappenschmidt; Christoph Engel; Norbert Arnold; Bernd Dworniczak; Kerstin Rhiem; Alfons Meindl; Rita K Schmutzler; Eric Hahnen
Journal:  Breast Cancer Res       Date:  2018-01-24       Impact factor: 6.466

9.  Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.

Authors:  Jan Hauke; Judit Horvath; Eva Groß; Andrea Gehrig; Ellen Honisch; Karl Hackmann; Gunnar Schmidt; Norbert Arnold; Ulrike Faust; Christian Sutter; Julia Hentschel; Shan Wang-Gohrke; Mateja Smogavec; Bernhard H F Weber; Nana Weber-Lassalle; Konstantin Weber-Lassalle; Julika Borde; Corinna Ernst; Janine Altmüller; Alexander E Volk; Holger Thiele; Verena Hübbel; Peter Nürnberg; Katharina Keupp; Beatrix Versmold; Esther Pohl; Christian Kubisch; Sabine Grill; Victoria Paul; Natalie Herold; Nadine Lichey; Kerstin Rhiem; Nina Ditsch; Christian Ruckert; Barbara Wappenschmidt; Bernd Auber; Andreas Rump; Dieter Niederacher; Thomas Haaf; Juliane Ramser; Bernd Dworniczak; Christoph Engel; Alfons Meindl; Rita K Schmutzler; Eric Hahnen
Journal:  Cancer Med       Date:  2018-03-09       Impact factor: 4.452

10.  Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

Authors:  Bernadette A M Heemskerk-Gerritsen; Agnes Jager; Linetta B Koppert; A Inge-Marie Obdeijn; Margriet Collée; Hanne E J Meijers-Heijboer; Denise J Jenner; Hester S A Oldenburg; Klaartje van Engelen; Jakob de Vries; Christi J van Asperen; Peter Devilee; Marinus J Blok; C Marleen Kets; Margreet G E M Ausems; Caroline Seynaeve; Matti A Rookus; Maartje J Hooning
Journal:  Breast Cancer Res Treat       Date:  2019-07-13       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.